PT  - JOURNAL ARTICLE
AU  - Ane Uranga
AU  - Pedro Pablo Espana
AU  - Alberto Capelastegui
AU  - Rosa Díez
AU  - Amaia Bilbao
AU  - Carmen Mar
AU  - Edurne Bereciartua
TI  - Prognostic power of biomarkers to predict in-hospital and postdischarge mortality in community acquired pneumonia
DP  - 2013 Sep 01
TA  - European Respiratory Journal
PG  - 5042
VI  - 42
IP  - Suppl 57
4099  - http://erj.ersjournals.com/content/42/Suppl_57/5042.short
4100  - http://erj.ersjournals.com/content/42/Suppl_57/5042.full
SO  - Eur Respir J2013 Sep 01; 42
AB  - Background:Recently, an extensive research has gone into identifying the predictive value of biomarkers for long term mortality in community-acquired pneumonia (CAP).Objective:The aim of this study was to evaluate the utility of inflammatory biomarkers measured on admission to predict mortality in patients with CAP.Methods:We prospectively included patients over 18 years old for a period of one year. Procalcitonin (PCT), C reactive protein (CRP) and Pro adrenomedullin (ProADM) levels were were compared according to in-hospital mortality, 30, 90 and 180-day mortality, and 1 year mortality, by means of the nonparametric Wilcoxon test. In addition, the predictive accuracy of each biomarker for mortality was analysed by means of logistic regression models, and the AUC was used to measure the predictive ability of each biomarker.Results:A total of 610 patients with diagnosis of CAP were included in our study and samples for biomarkers could be extracted in 491 of them. PCT and ProADM levels were significantly higher for short, medium and long term mortality. ProADM was the best biomarker in predicting complications. Figure 1 shows the results of the predictive ability of each biomarker for mortality.Conclusions:ProADM is a powerful tool not only for the prediction of short and medium mortality, but also for long term mortality.